Future of IgAN Treatment and Clinical Pearls for Disease Management
Cheung comments on new and future IgAN treatment, and shares clinical pearls with other providers.
Read More
Data Considerations of Novel Immunotherapies for IgAN
Cheung shares his approach to using novel immunotherapies in IgAN to prevent infection.
Dual Inhibition of BLyS and APRIL in IgAN
Cheung reviews the rationale for dual inhibition of BLyS and APRIL in IgAN, as well as the clinical impact of investigational agents on IgAN.
The Pathophysiology of IgAN and Use of Immunomodulating Therapies
An expert nephrologist provides an overview of the pathophysiology of IgAN before discussing new immunomodulating therapies in clinical trials.
Unmet Needs In Managing IgAN
Chee Kay Cheung, MBCHB, MRCP, PhD, discusses unmet needs in the management of IgAN, commenting on the need for new medication and highlighting budesonide and SGLT2 inhibitors.
Embracing Newer Agents in IgAN
An expert nephrologist shares his opinion on newer treatments of IgAN such as budesonide and SGLT2 inhibitors, commenting that patients with greater disease progression stand to benefit the most from these treatments.
Recent Agents for Treatment of IgAN
Chee Kay Cheung, MBCHB, MRCP, PhD, reviews newly approved agents for the treatment of IgAN, focusing on SGLT2 inhibitors, budesonide, and sparsentan.
Standard of Care for Patients With IgAN
Chee Kay Cheung, MBCHB, MRCP, PhD, comments on optimized supportive care for patients with IgAN, which monitors things like blood pressure, diet, and lifestyle.
Burden of Immunoglobulin A Nephropathy (IgAN) and Risk Factors
Chee Kay Cheung, MBCHB, MRCP, PhD, reviews the disease burden and prevalence of immunoglobulin A nephropathy (IgAN), as well as risk factors for disease progression.
